Show simple item record

dc.contributor.authorPagonabarraga, Javier
dc.contributor.authorPiñol Ripoll, Gerard
dc.contributor.authorCardozo, Adriana
dc.contributor.authorSanz, Pilar
dc.contributor.authorPuente, Víctor
dc.contributor.authorOtermín, Pilar
dc.contributor.authorLegarda, Inés
dc.contributor.authorDelgado, Tania
dc.contributor.authorSerrano, Carmen
dc.contributor.authorBalaguer, Ernest
dc.contributor.authorAguirregomozcorta, María
dc.contributor.authorÁlvarez, Ramiro
dc.contributor.authorKulisevsky, Jaime J.
dc.date.accessioned2016-03-30T08:31:45Z
dc.date.available2016-03-30T08:31:45Z
dc.date.issued2015
dc.identifier.issn2090-8083
dc.identifier.urihttp://hdl.handle.net/10459.1/56770
dc.description.abstractSleep disturbances occur frequently in patients with Parkinson’s disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8.9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson’s Disease Sleep Scale (PDSS). The newly designed Parkinson’s Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from 3.4 ± 0.9 to 1.9 ± 1.4; 𝑃 < 0.0001). Rotigotine also significantly improved nocturnal motor symptoms (𝑃 < 0.0001), restless legs-like symptoms (𝑃 < 0.005), and nocturia (𝑃 = 0.004). Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.ca_ES
dc.language.isoengca_ES
dc.publisherHindawi Publishing Corporationca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1155/2015/131508ca_ES
dc.relation.ispartofParkinson’s Disease, 2015, vol. 2015, id. 131508ca_ES
dc.rightscc-by, (c) Pagonabarraga et al., 2015ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleTransdermal rotigotine improves sleep fragmentation in parkinson’s disease: results of the multicenter, prospective SLEEP-FRAM studyca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1155/2015/131508


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Pagonabarraga et al., 2015
Except where otherwise noted, this item's license is described as cc-by, (c) Pagonabarraga et al., 2015